All In Biotech

BLA 208157 · Baxter Hlthcare Corp

Myxredlin

Insulin Human · Intravenous · Insulin

Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jun 20, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,803

844 Phase 3, 184 recruiting

FAERS reports

6,745

5,542 serious, 779 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 7, 2025.

MYXREDLIN is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. MYXREDLIN is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 ).

Mechanism: The primary activity of insulin, including MYXREDLIN is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 20, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • MYXREDLIN · INSULIN HUMAN 100 UNITS/100ML (1 UNIT/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Human" as an intervention, any sponsor and status, largest first.

All 3,803 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased966
  • hypoglycaemia434
  • drug ineffective380
  • dyspnoea331
  • hyperglycaemia329
  • diarrhoea325
  • blood glucose decreased295
  • off label use291
  • headache257
  • nausea250
  • fall246
  • weight decreased242

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200454
200554
200644
200773
200869
200967
201076
2011100
201296
2013160
2014369
2015909
2016196
2017143
2018385
2019349
2020310
2021410
2022665
2023607
2024651
2025585
2026373

Recalls

1 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.